Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: CIRBP

Gene summary for CIRBP

Gene summary.

Gene information	Species	Human
	Gene symbol	CIRBP
	Gene ID	1153
	Gene name	cold inducible RNA binding protein
	Gene Alias	CIRP
	Cytomap	19p13.3
	Gene Type	protein-coding
	GO ID	GO:0000375
	UniProtAcc	Q14011

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
1153	CIRBP	052099_1652-all-cells	Human	Prostate	BPH	6.05e-04	-3.23e-01	0.1038
1153	CIRBP	Dong_P1	Human	Prostate	Tumor	7.62e-23	-4.24e-02	0.035
1153	CIRBP	Dong_P3	Human	Prostate	Tumor	5.90e-29	5.21e-01	0.0278
1153	CIRBP	Dong_P4	Human	Prostate	Tumor	5.59e-08	4.86e-01	0.0292
1153	CIRBP	Dong_P5	Human	Prostate	Tumor	4.96e-16	-7.42e-02	0.053
1153	CIRBP	P7	Human	Prostate	Tumor	1.09e-25	1.33e+00	-0.1025
1153	CIRBP	P10	Human	Prostate	Tumor	1.59e-08	9.43e-01	-0.0902
1153	CIRBP	GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002	Human	Prostate	Tumor	1.29e-02	-3.96e-02	0.1602
1153	CIRBP	GSM5353228_PA_PR5199-640K_Pool_1_3_S108_L004	Human	Prostate	Tumor	2.53e-02	2.18e-01	0.1537
1153	CIRBP	GSM5353232_PA_PR5249_T1_S3_L001	Human	Prostate	Tumor	1.88e-05	-3.50e-01	0.1439
1153	CIRBP	GSM5353236_PA_PR5251_T1_S7_L001	Human	Prostate	Tumor	2.19e-05	3.49e-01	0.1608
1153	CIRBP	GSM5353240_PA_PR5254_T1_S15_L001	Human	Prostate	Tumor	6.92e-12	1.17e-01	0.1575
1153	CIRBP	GSM5353243_PA_PR5261_T1_S23_L002	Human	Prostate	Tumor	9.50e-17	-2.43e-01	0.1545
1153	CIRBP	GSM5353244_PA_PR5261_T2_S24_L002	Human	Prostate	Tumor	1.17e-14	-1.81e-01	0.1569
1153	CIRBP	GSM5353247_PA_PR5269_3_S27_L002	Human	Prostate	Tumor	3.32e-02	8.29e-06	0.1532
1153	CIRBP	GSM5353248_PA_PR5269_4_S28_L002	Human	Prostate	Tumor	3.65e-06	7.97e-02	0.1541
1153	CIRBP	P1_S1_AK	Human	Skin	AK	2.09e-14	-3.53e-01	-0.3399
1153	CIRBP	P2_S3_AK	Human	Skin	AK	2.40e-09	-2.36e-01	-0.3287
1153	CIRBP	P2_S4_SCCIS	Human	Skin	SCCIS	1.73e-10	-4.45e-01	-0.3043
1153	CIRBP	P3_S6_AK	Human	Skin	AK	2.08e-15	-6.07e-01	-0.3256

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00083809	Breast	Precancer	RNA splicing	65/1080	434/18723	1.27e-12	2.53e-10	65
GO:00434849	Breast	Precancer	regulation of RNA splicing	34/1080	148/18723	2.66e-12	4.75e-10	34
GO:00064179	Breast	Precancer	regulation of translation	67/1080	468/18723	4.71e-12	7.64e-10	67
GO:00457279	Breast	Precancer	positive regulation of translation	32/1080	136/18723	5.89e-12	9.27e-10	32
GO:00003759	Breast	Precancer	RNA splicing, via transesterification reactions	52/1080	324/18723	1.74e-11	2.22e-09	52
GO:00003779	Breast	Precancer	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	51/1080	320/18723	3.55e-11	4.04e-09	51
GO:00003989	Breast	Precancer	mRNA splicing, via spliceosome	51/1080	320/18723	3.55e-11	4.04e-09	51
GO:00342509	Breast	Precancer	positive regulation of cellular amide metabolic process	33/1080	162/18723	1.72e-10	1.77e-08	33
GO:00480249	Breast	Precancer	regulation of mRNA splicing, via spliceosome	22/1080	101/18723	5.29e-08	3.18e-06	22
GO:19033118	Breast	Precancer	regulation of mRNA metabolic process	38/1080	288/18723	1.63e-06	5.97e-05	38
GO:00506848	Breast	Precancer	regulation of mRNA processing	23/1080	137/18723	3.49e-06	1.13e-04	23
GO:00092667	Breast	Precancer	response to temperature stimulus	27/1080	178/18723	3.85e-06	1.21e-04	27
GO:00313309	Breast	Precancer	negative regulation of cellular catabolic process	34/1080	262/18723	8.16e-06	2.20e-04	34
GO:00064028	Breast	Precancer	mRNA catabolic process	31/1080	232/18723	1.12e-05	2.93e-04	31
GO:00064018	Breast	Precancer	RNA catabolic process	34/1080	278/18723	2.88e-05	6.39e-04	34
GO:19033129	Breast	Precancer	negative regulation of mRNA metabolic process	16/1080	92/18723	6.70e-05	1.35e-03	16
GO:00093148	Breast	Precancer	response to radiation	47/1080	456/18723	8.39e-05	1.62e-03	47
GO:00098959	Breast	Precancer	negative regulation of catabolic process	36/1080	320/18723	9.92e-05	1.83e-03	36
GO:00346558	Breast	Precancer	nucleobase-containing compound catabolic process	42/1080	407/18723	1.91e-04	3.06e-03	42
GO:00331207	Breast	Precancer	positive regulation of RNA splicing	9/1080	37/18723	1.96e-04	3.10e-03	9

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

CIRBP

SNV

Missense_Mutation

c.820N>A

p.Val274Met

p.V274M

protein_coding

tolerated_low_confidence(0.09)

benign(0.017)

TCGA-A8-A09I-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

anastrozole

CIRBP

SNV

Missense_Mutation

rs749046630

c.493N>A

p.Asp165Asn

p.D165N

protein_coding

deleterious(0)

possibly_damaging(0.632)

TCGA-A8-A0AD-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

CIRBP

SNV

Missense_Mutation

rs148277498

c.791N>A

p.Arg264His

p.R264H

protein_coding

deleterious_low_confidence(0.03)

benign(0)

TCGA-E2-A14Z-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

arimidex

CIRBP

SNV

Missense_Mutation

c.758C>G

p.Ser253Cys

p.S253C

protein_coding

tolerated_low_confidence(0.06)

benign(0.146)

TCGA-E2-A1IN-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

arimidex

CIRBP

SNV

Missense_Mutation

c.80C>T

p.Ser27Leu

p.S27L

protein_coding

deleterious(0)

probably_damaging(0.975)

TCGA-C5-A7UH-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Chemotherapy

cisplatin

CIRBP

SNV

Missense_Mutation

novel

c.643C>G

p.Gln215Glu

p.Q215E

protein_coding

tolerated_low_confidence(0.06)

benign(0)

TCGA-DS-A0VN-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

CIRBP

SNV

Missense_Mutation

c.98N>T

p.Ser33Phe

p.S33F

protein_coding

deleterious(0.04)

probably_damaging(0.986)

TCGA-EA-A3HQ-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

CIRBP

SNV

Missense_Mutation

c.731N>A

p.Arg244Lys

p.R244K

protein_coding

tolerated_low_confidence(0.06)

benign(0)

TCGA-AA-A01D-01

Colorectum

colon adenocarcinoma

Female

<65

III/IV

Chemotherapy

capecitabine

CIRBP

SNV

Missense_Mutation

rs11555031

c.49N>G

p.Thr17Ala

p.T17A

protein_coding

deleterious(0)

probably_damaging(0.988)

TCGA-AA-A02R-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

CIRBP

SNV

Missense_Mutation

c.5N>T

p.Ala2Val

p.A2V

protein_coding

deleterious(0)

possibly_damaging(0.526)

TCGA-AG-A02N-01

Colorectum

rectum adenocarcinoma

Male

>=65

I/II

Chemotherapy

folinic

Page: 1 2 3 4

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1